Dyne Therapeutics (NASDAQ:DYN) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report published on Friday morning,Benzinga reports. They currently have a $55.00 target price on the stock.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective on the stock. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Finally, Royal Bank of Canada started coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They set an “outperform” rating and a $45.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $49.91.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $15.87 on Friday. Dyne Therapeutics has a one year low of $14.79 and a one year high of $47.45. The company has a market cap of $1.62 billion, a P/E ratio of -4.46 and a beta of 1.16. The business has a fifty day moving average of $27.29 and a two-hundred day moving average of $34.15.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Sell-side analysts predict that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In related news, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $33.10, for a total value of $25,884.20. Following the transaction, the director now owns 15,962 shares in the company, valued at approximately $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,742 shares of company stock worth $1,443,246 in the last three months. Company insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. Point72 DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the third quarter worth about $36,000. US Bancorp DE raised its holdings in shares of Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at about $62,000. Finally, KBC Group NV boosted its holdings in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.